Cargando…

Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model

Alzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Xixia, Hou, Yujun, Meng, Qiong, Croteau, Deborah L., Wei, Yong, De, Supriyo, Becker, Kevin G., Bohr, Vilhelm A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520302/
https://www.ncbi.nlm.nih.gov/pubmed/36185477
http://dx.doi.org/10.3389/fnagi.2022.993615
_version_ 1784799593224994816
author Chu, Xixia
Hou, Yujun
Meng, Qiong
Croteau, Deborah L.
Wei, Yong
De, Supriyo
Becker, Kevin G.
Bohr, Vilhelm A.
author_facet Chu, Xixia
Hou, Yujun
Meng, Qiong
Croteau, Deborah L.
Wei, Yong
De, Supriyo
Becker, Kevin G.
Bohr, Vilhelm A.
author_sort Chu, Xixia
collection PubMed
description Alzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleotide (NAD(+)) precursor, nicotinamide riboside (NR), reduced the brain features of AD, including neuroinflammation, deoxyribonucleic acid (DNA) damage, synaptic dysfunction, and cognitive impairment. However, the impact of NR administration on the intestinal microbiota of AD remains unknown. In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice. Compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower and the microbiota composition and enterotype were significantly different. Moreover, there were gender differences in gut microbiome between female and male AD mice. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice. This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD.
format Online
Article
Text
id pubmed-9520302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95203022022-09-30 Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model Chu, Xixia Hou, Yujun Meng, Qiong Croteau, Deborah L. Wei, Yong De, Supriyo Becker, Kevin G. Bohr, Vilhelm A. Front Aging Neurosci Neuroscience Alzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleotide (NAD(+)) precursor, nicotinamide riboside (NR), reduced the brain features of AD, including neuroinflammation, deoxyribonucleic acid (DNA) damage, synaptic dysfunction, and cognitive impairment. However, the impact of NR administration on the intestinal microbiota of AD remains unknown. In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice. Compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower and the microbiota composition and enterotype were significantly different. Moreover, there were gender differences in gut microbiome between female and male AD mice. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice. This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520302/ /pubmed/36185477 http://dx.doi.org/10.3389/fnagi.2022.993615 Text en Copyright © 2022 Chu, Hou, Meng, Croteau, Wei, De, Becker and Bohr. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Chu, Xixia
Hou, Yujun
Meng, Qiong
Croteau, Deborah L.
Wei, Yong
De, Supriyo
Becker, Kevin G.
Bohr, Vilhelm A.
Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title_full Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title_fullStr Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title_full_unstemmed Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title_short Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
title_sort nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in alzheimer’s mouse model
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520302/
https://www.ncbi.nlm.nih.gov/pubmed/36185477
http://dx.doi.org/10.3389/fnagi.2022.993615
work_keys_str_mv AT chuxixia nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT houyujun nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT mengqiong nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT croteaudeborahl nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT weiyong nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT desupriyo nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT beckerkeving nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel
AT bohrvilhelma nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel